TherapeuticsMD (NASDAQ:TXMD) Stock Price Up 5.8% – Should You Buy?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s stock price rose 5.8% during mid-day trading on Monday . The stock traded as high as $2.19 and last traded at $2.19. Approximately 29,789 shares changed hands during mid-day trading, an increase of 39% from the average daily volume of 21,472 shares. The stock had previously closed at $2.07.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

TherapeuticsMD Trading Up 5.8%

The firm has a market cap of $25.34 million, a price-to-earnings ratio of -219.00 and a beta of 0.56. The company has a 50 day moving average of $2.20 and a 200 day moving average of $1.87.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($6.12) by $6.07. The business had revenue of $0.89 million for the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative return on equity of 2.41% and a negative net margin of 18.83%.

Institutional Trading of TherapeuticsMD

Several hedge funds have recently added to or reduced their stakes in TXMD. Renaissance Technologies LLC raised its stake in TherapeuticsMD by 171.8% during the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after buying an additional 61,000 shares during the period. Citadel Advisors LLC raised its stake in shares of TherapeuticsMD by 125.5% in the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after purchasing an additional 19,073 shares during the period. Finally, Tejara Capital Ltd raised its stake in shares of TherapeuticsMD by 1.9% in the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after purchasing an additional 6,649 shares during the period. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.